Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?
Keith Speights, The Motley Fool
·4 min read

Fifteen billion dollars: That's how much Pfizer (NYSE: PFE) projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Since Pfizer's update, the U.S. government has ordered another 100 million doses of BNT162b2. Pfizer and BioNTech announced last week that they've begun a study to evaluate a third dose of BNT162b2.